Actively Recruiting
Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic Malignancies
Led by Abramson Cancer Center at Penn Medicine · Updated on 2025-07-31
20
Participants Needed
1
Research Sites
423 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this research study is to determine if frailty assessments can be used to predict how well patients aged 60 years and older will do after chemotherapy, CAR T-cell therapy, or allogeneic stem cell transplant.
CONDITIONS
Official Title
Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic Malignancies
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 60 years or older
- New diagnosis or suspected diagnosis of Acute Leukemia or MDS
- Able to provide consent to participate in the study
- Age 60 years or older with a hematologic malignancy
- Plan to undergo allogeneic blood or marrow transplantation or CAR T-cell therapy
- Able to provide consent to participate in the study
You will not qualify if you...
null
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104
Actively Recruiting
Research Team
S
Shannon McCurdy, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here